LumiraDx Announces Proposed Public Offering of Common Shares

LONDON, July 19, 2022 /PRNewswire/ — LumiraDx Limited (Nasdaq: LMDX), a next-generation point-of-care (POC) diagnostics company, today announced that it has launched an underwritten public offering of 40,000,000 common shares. All shares in the proposed offering must be sold by LumiraDx. In addition, LumiraDx intends to grant the underwriters a 30-day option to purchase up to 6,000,000 additional common shares at the public offering price. The proposed offer is subject to market and other conditions, and there can be no assurance that or when the offer will be completed, or the actual size or terms of the offer.

LumiraDx plans to use the net proceeds of this offering, along with its existing cash and cash equivalents, primarily for general corporate purposes, including working capital with respect to R&D, business development and operations. sales and marketing and capital expenditures in the normal course.

Goldman Sachs & Co. LLC, Evercore ISI, SVB Securities and Raymond James act as joint bookrunners for the proposed offering.

The proposed offering of these securities will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to these securities may be obtained free of charge from one of the bookrunners of the proposed offer: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by phone at (866) 471-2526 or by email at [email protected]; Evercore Group LLC, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by phone at (888) 474-0200, or by email at [email protected]; SVB Securities LLC, c/o Department of Trade Unions, 53 State Street, 40th Floor, Boston, MA 02109, by phone at (800) 808-7525, ext. 6105, or by email at [email protected]; Where Raymond James & Associates, Inc., Attn: Department of Labor Unions, 880 Carillon Parkway, St. Petersburg, Florida 33716, by phone at (800) 248-8863, or by email at [email protected]

A registration statement, including a prospectus, which is preliminary and subject to completion, relating to these securities has been filed with the United States Securities and Exchange Commission (“SEC”), but is not yet entered into force. These securities may not be sold or offers to buy may be accepted prior to the effective date of the registration statement. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, securities, and there will be no sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or territory.

About LumiraDx

LumiraDx (Nasdaq: LMDX) is a next-generation point-of-care diagnostics company transforming community healthcare. Founded in 2014, LumiraDx manufactures and markets an innovative diagnostic platform that supports a wide range of tests with comparable performance from the lab to the point-of-care. LumiraDx’s diagnostic testing solutions are deployed by governments and major healthcare facilities in laboratories, emergency care, medical offices, pharmacies, schools and workplaces to screen, diagnose and monitor the well-being as well as illness. LumiraDx has more than 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes and bleeding disorders, all on the LumiraDx platform. Additionally, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-effective COVID-19 testing solutions from the lab to the point of need. LumiraDx is based in the UK with over 1600 employees worldwide.

Forward-looking statements

This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties. important. These statements address a variety of matters, including, without limitation, the Company’s expectations regarding the sale of its common stock under the proposed offer, the use of proceeds from the proposed offer, the grant of the option to purchase additional shares and other statements that are not purely statements of historical fact. These forward-looking statements include information about the terms of the offer, our ability to complete the offer and the intended use of the proceeds. Words such as “expects”, “intends”, “plans”, “believes”, “anticipates”, “estimates” and variations of such words and similar expressions are intended to identify such forward-looking statements.

Although we believe that the forward-looking statements contained in this press release are based on reasonable assumptions, you should be aware that many factors could cause actual results to differ materially from those contained in such forward-looking statements, including, but not limited to: economic, political and business conditions; the effect of COVID-19 on LumiraDx’s business and financial results; obtain or maintain regulatory approval, clearance or clearance for our testing; and the factors discussed under the heading “Risk Factors” in the preliminary prospectus relating to the securities, when available, in our annual report on Form 20-F for the year ended December 31, 2021which was filed with the SEC on April 13, 2022 and in other documents filed with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in our expectations with respect to such statements or any change in events, conditions or circumstances about which any statement is based.


Colleen McMillen
[email protected]

Quote Show original content to download multimedia:


Comments are closed.